NCT04299412View on ClinicalTrials.gov

Diagnostic Accuracy of the DPP II Assay

CompletedOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

July 30, 2020

Study Completion Date

September 30, 2020

Conditions
Acute Febrile IllnessMelioidosisDiagnoses Disease
Interventions
DEVICE

DPP Fever Panel II assay

Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds

Trial Locations (1)

Unknown

Menzies School of Health Research, Darwin

All Listed Sponsors
lead

Foundation for Innovative New Diagnostics, Switzerland

OTHER

NCT04299412 - Diagnostic Accuracy of the DPP II Assay | Biotech Hunter | Biotech Hunter